Difference between revisions of "Pyrotinib (Irene)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pyrotinib NCI Drug Dictionary]: An orally bioavailable, dual...") |
m |
||
| Line 8: | Line 8: | ||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
| − | * | + | * 2018-08-22: Initial conditional authorization |
==Also known as== | ==Also known as== | ||
Revision as of 13:32, 9 May 2023
General information
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells.
Route: PO
Extravasation: n/a
Diseases for which it is used
History of changes in NMPA indication
- 2018-08-22: Initial conditional authorization
Also known as
- Brand name: Irene